<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38793710</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">459</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12050459</ELocationID><Abstract><AbstractText>Understanding the antibody response to SARS-CoV-2, the virus responsible for COVID-19, is crucial to comprehending disease progression and the significance of vaccine and therapeutic development. The emergence of highly contagious variants poses a significant challenge to humoral immunity, underscoring the necessity of grasping the intricacies of specific antibodies. This review emphasizes the pivotal role of antibodies in shaping immune responses and their implications for diagnosing, preventing, and treating SARS-CoV-2 infection. It delves into the kinetics and characteristics of the antibody response to SARS-CoV-2 and explores current antibody-based diagnostics, discussing their strengths, clinical utility, and limitations. Furthermore, we underscore the therapeutic potential of SARS-CoV-2-specific antibodies, discussing various antibody-based therapies such as monoclonal antibodies, polyclonal antibodies, anti-cytokines, convalescent plasma, and hyperimmunoglobulin-based therapies. Moreover, we offer insights into antibody responses to SARS-CoV-2 vaccines, emphasizing the significance of neutralizing antibodies in order to confer immunity to SARS-CoV-2, along with emerging variants of concern (VOCs) and circulating Omicron subvariants. We also highlight challenges in the field, such as the risks of antibody-dependent enhancement (ADE) for SARS-CoV-2 antibodies, and shed light on the challenges associated with the original antigenic sin (OAS) effect and long COVID. Overall, this review intends to provide valuable insights, which are crucial to advancing sensitive diagnostic tools, identifying efficient antibody-based therapeutics, and developing effective vaccines to combat the evolving threat of SARS-CoV-2 variants on a global scale.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anoop</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5236-8515</Identifier><AffiliationInfo><Affiliation>Molecular Diagnostic Laboratory, National Institute of Biologicals, Noida 201309, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Prajna</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2242-0404</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>R. Ken Coit College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shekhar</LastName><ForeName>Ritu</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3397-6061</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9133-3983</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Omicron subvariants</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2-specific antibodies</Keyword><Keyword MajorTopicYN="N">antibody-dependent enhancement</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">diagnostic</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neutralizing monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">original antigenic sin</Keyword><Keyword MajorTopicYN="N">serological assays</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">variants of concern (VOC)</Keyword></KeywordList><CoiStatement>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38793710</ArticleId><ArticleId IdType="pmc">PMC11125746</ArticleId><ArticleId IdType="doi">10.3390/vaccines12050459</ArticleId><ArticleId IdType="pii">vaccines12050459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchenko V., Danilenko A., Kolosova N., Bragina M., Molchanova M., Bulanovich Y., Gorodov V., Leonov S., Gudymo A., Onkhonova G., et al. Diversity of gammacoronaviruses and deltacoronaviruses in wild birds and poultry in Russia. Sci. Rep. 2022;12:19412. doi: 10.1038/s41598-022-23925-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23925-z</ArticleId><ArticleId IdType="pmc">PMC9653423</ArticleId><ArticleId IdType="pubmed">36371465</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacroce L., Charitos I.A., Carretta D.M., De Nitto E., Lovero R. The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. J. Mol. Med. 2021;99:93&#x2013;106. doi: 10.1007/s00109-020-02012-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-020-02012-8</ArticleId><ArticleId IdType="pmc">PMC7710368</ArticleId><ArticleId IdType="pubmed">33269412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953&#x2013;1966. doi: 10.1056/NEJMoa030781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030781</ArticleId><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M.M., Khanom H., Farag E., Mim Z.T., Naidoo P., Mkhize-Kwitshana Z.L., Tibbo M., Islam A., Soares Magalhaes R.J., Hassan M.M. Global patterns of Middle East respiratory syndrome coronavirus (MERS-CoV) prevalence and seroprevalence in camels: A systematic review and meta-analysis. One Health. 2023;16:100561. doi: 10.1016/j.onehlt.2023.100561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.onehlt.2023.100561</ArticleId><ArticleId IdType="pmc">PMC10166617</ArticleId><ArticleId IdType="pubmed">37200564</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelghany T.M., Ganash M., Bakri M.M., Qanash H., Al-Rajhi A.M.H., Elhussieny N.I. SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions. Biomed. J. 2021;44:86&#x2013;93. doi: 10.1016/j.bj.2020.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.10.008</ArticleId><ArticleId IdType="pmc">PMC7603957</ArticleId><ArticleId IdType="pubmed">33602634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K., Yuan S., Yuen K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 2020;9:221&#x2013;236. doi: 10.1080/22221751.2020.1719902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1719902</ArticleId><ArticleId IdType="pmc">PMC7067204</ArticleId><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubina R., Dziedzic A. Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics. Diagnostics. 2020;10:434. doi: 10.3390/diagnostics10060434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10060434</ArticleId><ArticleId IdType="pmc">PMC7345211</ArticleId><ArticleId IdType="pubmed">32604919</ArticleId></ArticleIdList></Reference><Reference><Citation>Teymouri M., Mollazadeh S., Mortazavi H., Naderi Ghale-Noie Z., Keyvani V., Aghababaei F., Hamblin M.R., Abbaszadeh-Goudarzi G., Pourghadamyari H., Hashemian S.M.R., et al. Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19. Pathol. Res. Pract. 2021;221:153443. doi: 10.1016/j.prp.2021.153443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2021.153443</ArticleId><ArticleId IdType="pmc">PMC8045416</ArticleId><ArticleId IdType="pubmed">33930607</ArticleId></ArticleIdList></Reference><Reference><Citation>Guruprasad L. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition. Proteins. 2020;88:1387&#x2013;1393. doi: 10.1002/prot.25967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.25967</ArticleId><ArticleId IdType="pmc">PMC7323375</ArticleId><ArticleId IdType="pubmed">32543705</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Nunez J.J., Munoz-Valle J.F., Torres-Hernandez P.C., Hernandez-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines. 2021;9:1376. doi: 10.3390/vaccines9121376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121376</ArticleId><ArticleId IdType="pmc">PMC8706198</ArticleId><ArticleId IdType="pubmed">34960121</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallano A., Ascione A., Flego M. Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. Int. Rev. Immunol. 2022;41:393&#x2013;413. doi: 10.1080/08830185.2021.1929205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2021.1929205</ArticleId><ArticleId IdType="pmc">PMC8442988</ArticleId><ArticleId IdType="pubmed">34494500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubonja-Sonje M., Baticic L., Abram M., Cekinovic Grbesa D. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies. J. Virol. Methods. 2021;293:114173. doi: 10.1016/j.jviromet.2021.114173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114173</ArticleId><ArticleId IdType="pmc">PMC8078047</ArticleId><ArticleId IdType="pubmed">33930473</ArticleId></ArticleIdList></Reference><Reference><Citation>Guevara-Hoyer K., Fuentes-Antras J., De la Fuente-Munoz E., Rodriguez de la Pena A., Vinuela M., Cabello-Clotet N., Estrada V., Culebras E., Delgado-Iribarren A., Martinez-Novillo M., et al. Serological Tests in the Detection of SARS-CoV-2 Antibodies. Diagnostics. 2021;11:678. doi: 10.3390/diagnostics11040678.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11040678</ArticleId><ArticleId IdType="pmc">PMC8069538</ArticleId><ArticleId IdType="pubmed">33918840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidiq Z., Hanif M., Dwivedi K.K., Chopra K.K. Benefits and limitations of serological assays in COVID-19 infection. Indian J. Tuberc. 2020;67:S163&#x2013;S166. doi: 10.1016/j.ijtb.2020.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2020.07.034</ArticleId><ArticleId IdType="pmc">PMC7409828</ArticleId><ArticleId IdType="pubmed">33308664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cota G., Freire M.L., de Souza C.S., Pedras M.J., Saliba J.W., Faria V., Alves L.L., Rabello A., Avelar D.M. Diagnostic performance of commercially available COVID-19 serology tests in Brazil. Int. J. Infect. Dis. 2020;101:382&#x2013;390. doi: 10.1016/j.ijid.2020.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.008</ArticleId><ArticleId IdType="pmc">PMC7544564</ArticleId><ArticleId IdType="pubmed">33039612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Muller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465&#x2013;469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong F., Wei H.X., Li Q., Liu L., Li B. Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis. Front. Mol. Biosci. 2021;8:682405. doi: 10.3389/fmolb.2021.682405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.682405</ArticleId><ArticleId IdType="pmc">PMC8343015</ArticleId><ArticleId IdType="pubmed">34368226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong D.S.Y., Fragkou P.C., Schweitzer V.A., Chemaly R.F., Moschopoulos C.D., Skevaki C. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV). How to interpret and use COVID-19 serology and immunology tests. Clin. Microbiol. Infect. 2021;27:981&#x2013;986. doi: 10.1016/j.cmi.2021.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.001</ArticleId><ArticleId IdType="pmc">PMC8106522</ArticleId><ArticleId IdType="pubmed">33975005</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan X., Yang Y., Du L. Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines. Expert Rev. Vaccines. 2023;22:422&#x2013;439. doi: 10.1080/14760584.2023.2211153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2211153</ArticleId><ArticleId IdType="pmc">PMC10355161</ArticleId><ArticleId IdType="pubmed">37161869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 2022;28:202&#x2013;221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671&#x2013;681. doi: 10.1016/S0140-6736(21)00234-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00234-8</ArticleId><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Salleh M.Z., Norazmi M.N., Deris Z.Z. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ. 2022;10:e13083. doi: 10.7717/peerj.13083.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.13083</ArticleId><ArticleId IdType="pmc">PMC8917804</ArticleId><ArticleId IdType="pubmed">35287350</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraiman J., Erviti J., Jones M., Greenland S., Whelan P., Kaplan R.M., Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022;40:5798&#x2013;5805. doi: 10.1016/j.vaccine.2022.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.036</ArticleId><ArticleId IdType="pmc">PMC9428332</ArticleId><ArticleId IdType="pubmed">36055877</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X.L., Cheng J.S., Gong H.L., Yuan M.D., Zhao X.H., Li Z., Wei D.X. Advances in the design and development of SARS-CoV-2 vaccines. Mil. Med. Res. 2021;8:67. doi: 10.1186/s40779-021-00360-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-021-00360-1</ArticleId><ArticleId IdType="pmc">PMC8674100</ArticleId><ArticleId IdType="pubmed">34911569</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanaparthy R., Mohan G., Vasireddy D., Atluri P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez. Med. 2021;29:328&#x2013;338. doi: 10.53854/liim-2903-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.53854/liim-2903-3</ArticleId><ArticleId IdType="pmc">PMC8805485</ArticleId><ArticleId IdType="pubmed">35146337</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine. N. Engl. J. Med. 2021;385:1172&#x2013;1183. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynia M.K., Beaty L.E., Bennett T.D., Carlson N.E., Davis C.B., Kwan B.M., Mayer D.A., Ong T.C., Russell S., Steele J.D., et al. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2023;163:1061&#x2013;1070. doi: 10.1016/j.chest.2022.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.10.020</ArticleId><ArticleId IdType="pmc">PMC9613796</ArticleId><ArticleId IdType="pubmed">36441040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang Y.C., Lu R.M., Su S.C., Chiang P.Y., Ko S.H., Ke F.Y., Liang K.H., Hsieh T.Y., Wu H.C. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J. Biomed. Sci. 2022;29:1. doi: 10.1186/s12929-021-00784-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00784-w</ArticleId><ArticleId IdType="pmc">PMC8724751</ArticleId><ArticleId IdType="pubmed">34983527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotundo S., Vecchio E., Abatino A., Giordano C., Mancuso S., Tassone M.T., Costa C., Russo A., Trecarichi E.M., Cuda G., et al. Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2. Int. J. Infect. Dis. 2022;124:55&#x2013;64. doi: 10.1016/j.ijid.2022.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.09.016</ArticleId><ArticleId IdType="pmc">PMC9477616</ArticleId><ArticleId IdType="pubmed">36116671</ArticleId></ArticleIdList></Reference><Reference><Citation>Farshadpour F., Taherkhani R. Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations. Med. Princ. Pract. 2021;30:422&#x2013;429. doi: 10.1159/000516693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516693</ArticleId><ArticleId IdType="pmc">PMC8339023</ArticleId><ArticleId IdType="pubmed">33882487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip M.S., Leung H.L., Li P.H., Cheung C.Y., Dutry I., Li D., Daeron M., Bruzzone R., Peiris J.S., Jaume M. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med. J. 2016;22:25&#x2013;31. doi: 10.1186/1753-6561-5-S1-P80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1753-6561-5-S1-P80</ArticleId><ArticleId IdType="pubmed">27390007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantaleo G., Correia B., Fenwick C., Joo V.S., Perez L. Antibodies to combat viral infections: Development strategies and progress. Nat. Rev. Drug Discov. 2022;21:676&#x2013;696. doi: 10.1038/s41573-022-00495-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00495-3</ArticleId><ArticleId IdType="pmc">PMC9207876</ArticleId><ArticleId IdType="pubmed">35725925</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S., Nampoothiri M. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch. Med. Res. 2020;51:482&#x2013;491. doi: 10.1016/j.arcmed.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7247499</ArticleId><ArticleId IdType="pubmed">32493627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav R., Chaudhary J.K., Jain N., Chaudhary P.K., Khanra S., Dhamija P., Sharma A., Kumar A., Handu S. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells. 2021;10:821. doi: 10.3390/cells10040821.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040821</ArticleId><ArticleId IdType="pmc">PMC8067447</ArticleId><ArticleId IdType="pubmed">33917481</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler C.G.K., Allon S.J., Nyquist S.K., Mbano I.M., Miao V.N., Tzouanas C.N., Cao Y., Yousif A.S., Bals J., Hauser B.M., et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020;181:1016&#x2013;1035.e19. doi: 10.1016/j.cell.2020.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S., Secchi M., Pirillo M.F., Tolazzi M., Borghi M., Brigatti C., De Angelis M.L., Baratella M., Bazzigaluppi E., Venturi G., et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 2021;12:2670. doi: 10.1038/s41467-021-22958-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22958-8</ArticleId><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>West R., Kobokovich A., Connell N., Gronvall G.K. COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals. Trends Microbiol. 2021;29:214&#x2013;223. doi: 10.1016/j.tim.2020.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2020.11.002</ArticleId><ArticleId IdType="pmc">PMC7836413</ArticleId><ArticleId IdType="pubmed">33234439</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnicelli A., Fiori B., Ricci R., Piano A., Bonadia N., Taddei E., Fantoni M., Murri R., Cingolani A., Barillaro C., et al. Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital. Intern. Emerg. Med. 2022;17:53&#x2013;64. doi: 10.1007/s11739-021-02750-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02750-8</ArticleId><ArticleId IdType="pmc">PMC8107418</ArticleId><ArticleId IdType="pubmed">33970428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K.L., Whitman J.D., Lacanienta N.P., Beckerdite E.W., Kastner S.A., Shy B.R., Goldgof G.M., Levine A.G., Bapat S.P., Stramer S.L., et al. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Clin. Infect. Dis. 2021;72:301&#x2013;308. doi: 10.1093/cid/ciaa979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa979</ArticleId><ArticleId IdType="pmc">PMC7454426</ArticleId><ArticleId IdType="pubmed">33501951</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijkers G., Murk J.L., Wintermans B., van Looy B., van den Berge M., Veenemans J., Stohr J., Reusken C., van der Pol P., Reimerink J. Differences in Antibody Kinetics and Functionality between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. J. Infect. Dis. 2020;222:1265&#x2013;1269. doi: 10.1093/infdis/jiaa463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa463</ArticleId><ArticleId IdType="pmc">PMC7454692</ArticleId><ArticleId IdType="pubmed">32726417</ArticleId></ArticleIdList></Reference><Reference><Citation>Padoan A., Sciacovelli L., Basso D., Negrini D., Zuin S., Cosma C., Faggian D., Matricardi P., Plebani M. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin. Chim. Acta. 2020;507:164&#x2013;166. doi: 10.1016/j.cca.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7194886</ArticleId><ArticleId IdType="pubmed">32343948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Feng Y., Mo X., Zheng P., Wang Q., Li P., Peng P., Liu X., Chen Z., Huang H., et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg. Microbes Infect. 2020;9:940&#x2013;948. doi: 10.1080/22221751.2020.1762515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1762515</ArticleId><ArticleId IdType="pmc">PMC7273175</ArticleId><ArticleId IdType="pubmed">32357808</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao T., Wang Y., Yuan J., Ye H., Wei L., Liao X., Wang H., Qian S., Wang Z., Liu L., et al. Early Viral Clearance and Antibody Kinetics of COVID-19 among Asymptomatic Carriers. Front. Med. 2021;8:595773. doi: 10.3389/fmed.2021.595773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.595773</ArticleId><ArticleId IdType="pmc">PMC8005564</ArticleId><ArticleId IdType="pubmed">33791320</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y., Wang X., Yuan J., Li T., Li J., et al. Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019. Clin. Infect. Dis. 2020;71:2027&#x2013;2034. doi: 10.1093/cid/ciaa344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa344</ArticleId><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A.S., Jones F.K., Nodoushani A., Kelly M., Becker M., Slater D., Mills R., Teng E., Kamruzzaman M., Garcia-Beltran W.F., et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 2020;5:eabe0367. doi: 10.1126/sciimmunol.abe0367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe0367</ArticleId><ArticleId IdType="pmc">PMC7857394</ArticleId><ArticleId IdType="pubmed">33033172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yongchen Z., Shen H., Wang X., Shi X., Li Y., Yan J., Chen Y., Gu B. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg. Microbes Infect. 2020;9:833&#x2013;836. doi: 10.1080/22221751.2020.1756699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1756699</ArticleId><ArticleId IdType="pmc">PMC7241531</ArticleId><ArticleId IdType="pubmed">32306864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Bae J.Y., Kwon K., Chang H.H., Lee W.K., Park H., Kim J., Choi I., Park M.S., Kim S.W. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. Sci. Rep. 2022;12:13491. doi: 10.1038/s41598-022-17605-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17605-1</ArticleId><ArticleId IdType="pmc">PMC9356129</ArticleId><ArticleId IdType="pubmed">35931794</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.X., Liu B.Z., Deng H.J., Wu G.C., Deng K., Chen Y.K., Liao P., Qiu J.F., Lin Y., Cai X.F., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020;26:845&#x2013;848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165878. doi: 10.1016/j.bbadis.2020.165878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2020.165878</ArticleId><ArticleId IdType="pmc">PMC7293463</ArticleId><ArticleId IdType="pubmed">32544429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.K., Sue S.C., Yu T.H., Hsieh C.M., Tsai C.K., Chiang Y.C., Lee S.J., Hsiao H.H., Wu W.J., Chang W.L., et al. Modular organization of SARS coronavirus nucleocapsid protein. J. Biomed. Sci. 2006;13:59&#x2013;72. doi: 10.1007/s11373-005-9035-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11373-005-9035-9</ArticleId><ArticleId IdType="pmc">PMC7089556</ArticleId><ArticleId IdType="pubmed">16228284</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 2016;3:237&#x2013;261. doi: 10.1146/annurev-virology-110615-042301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-110615-042301</ArticleId><ArticleId IdType="pmc">PMC5457962</ArticleId><ArticleId IdType="pubmed">27578435</ArticleId></ArticleIdList></Reference><Reference><Citation>Khailany R.A., Safdar M., Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682. doi: 10.1016/j.genrep.2020.100682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2020.100682</ArticleId><ArticleId IdType="pmc">PMC7161481</ArticleId><ArticleId IdType="pubmed">32300673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ching L., Chang S.P., Nerurkar V.R. COVID-19 Special Column: Principles Behind the Technology for Detecting SARS-CoV-2, the Cause of COVID-19. Hawaii J. Health Soc. Welf. 2020;79:136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226308</ArticleId><ArticleId IdType="pubmed">32432217</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbiani D.F., Gaebler C., Muecksch F., Lorenzi J.C.C., Wang Z., Cho A., Agudelo M., Barnes C.O., Gazumyan A., Finkin S., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437&#x2013;442. doi: 10.1038/s41586-020-2456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2456-9</ArticleId><ArticleId IdType="pmc">PMC7442695</ArticleId><ArticleId IdType="pubmed">32555388</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer P.J.M., Caniels T.G., van der Straten K., Snitselaar J.L., Aldon Y., Bangaru S., Torres J.L., Okba N.M.A., Claireaux M., Kerster G., et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643&#x2013;650. doi: 10.1126/science.abc5902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5902</ArticleId><ArticleId IdType="pmc">PMC7299281</ArticleId><ArticleId IdType="pubmed">32540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers T.F., Zhao F., Huang D., Beutler N., Burns A., He W.T., Limbo O., Smith C., Song G., Woehl J., et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956&#x2013;963. doi: 10.1126/science.abc7520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc7520</ArticleId><ArticleId IdType="pmc">PMC7299280</ArticleId><ArticleId IdType="pubmed">32540903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost S.J., Gilchuk P., Case J.B., Binshtein E., Chen R.E., Nkolola J.P., Schafer A., Reidy J.X., Trivette A., Nargi R.S., et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443&#x2013;449. doi: 10.1038/s41586-020-2548-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2548-6</ArticleId><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer C.K., Ayres F., Hermanus T., Madzivhandila M., Kgagudi P., Oosthuysen B., Lambson B.E., de Oliveira T., Vermeulen M., van der Berg K., et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27:622&#x2013;625. doi: 10.1038/s41591-021-01285-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuri-Cervantes L., Pampena M.B., Meng W., Rosenfeld A.M., Ittner C.A.G., Weisman A.R., Agyekum R.S., Mathew D., Baxter A.E., Vella L.A., et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 2020;5:eabd7114. doi: 10.1126/sciimmunol.abd7114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd7114</ArticleId><ArticleId IdType="pmc">PMC7402634</ArticleId><ArticleId IdType="pubmed">32669287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Carpp L.N., Miller H.E.R., Zager M., Newell E.W., Gottardo R. Single-cell immunology of SARS-CoV-2 infection. Nat. Biotechnol. 2022;40:30&#x2013;41. doi: 10.1038/s41587-021-01131-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01131-y</ArticleId><ArticleId IdType="pmc">PMC9414121</ArticleId><ArticleId IdType="pubmed">34931002</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D., Rajsbaum R., Shi P.Y. Evasion of Type I Interferon by SARS-CoV-2. Cell Rep. 2020;33:108234. doi: 10.1016/j.celrep.2020.108234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H., Chan J.F., Wang Y., Yuen T.T., Chai Y., Hou Y., Shuai H., Yang D., Hu B., Huang X., et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study with Implications for the Pathogenesis of COVID-19. Clin. Infect. Dis. 2020;71:1400&#x2013;1409. doi: 10.1093/cid/ciaa410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa410</ArticleId><ArticleId IdType="pmc">PMC7184390</ArticleId><ArticleId IdType="pubmed">32270184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A., Salvati L., Maggi L., Annunziato F., Cosmi L. Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. Semin. Immunol. 2021;55:101508. doi: 10.1016/j.smim.2021.101508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101508</ArticleId><ArticleId IdType="pmc">PMC8547971</ArticleId><ArticleId IdType="pubmed">34728121</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D., Hammi I., Kihel A., El Idrissi Saik I., Guessous F., Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb. Pathog. 2021;153:104799. doi: 10.1016/j.micpath.2021.104799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa S.S., Prazeres D.M.F., Azevedo A.M., Marques M.P.C. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021;39:2190&#x2013;2200. doi: 10.1016/j.vaccine.2021.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.038</ArticleId><ArticleId IdType="pmc">PMC7987532</ArticleId><ArticleId IdType="pubmed">33771389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Hogan M.J., Weissman D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 2020;65:14&#x2013;20. doi: 10.1016/j.coi.2020.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2020.01.008</ArticleId><ArticleId IdType="pubmed">32244193</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai F., Tachibana M., Mizuguchi H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet. 2022;42:100432. doi: 10.1016/j.dmpk.2021.100432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dmpk.2021.100432</ArticleId><ArticleId IdType="pmc">PMC8585960</ArticleId><ArticleId IdType="pubmed">34974335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos R., Rutten L., van der Lubbe J.E.M., Bakkers M.J.G., Hardenberg G., Wegmann F., Zuijdgeest D., de Wilde A.H., Koornneef A., Verwilligen A., et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91. doi: 10.1038/s41541-020-00243-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00243-x</ArticleId><ArticleId IdType="pmc">PMC7522255</ArticleId><ArticleId IdType="pubmed">33083026</ArticleId></ArticleIdList></Reference><Reference><Citation>Stertman L., Palm A.E., Zarnegar B., Carow B., Lunderius Andersson C., Magnusson S.E., Carnrot C., Shinde V., Smith G., Glenn G., et al. The Matrix-M adjuvant: A critical component of vaccines for the 21st century. Hum. Vaccines Immunother. 2023;19:2189885. doi: 10.1080/21645515.2023.2189885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2189885</ArticleId><ArticleId IdType="pmc">PMC10158541</ArticleId><ArticleId IdType="pubmed">37113023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R., Vadrevu K.M., Jogdand H., Prasad S., Reddy S., Sarangi V., Ganneru B., Sapkal G., Yadav P., Abraham P., et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 2021;21:637&#x2013;646. doi: 10.1016/S1473-3099(20)30942-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30942-7</ArticleId><ArticleId IdType="pmc">PMC7825810</ArticleId><ArticleId IdType="pubmed">33485468</ArticleId></ArticleIdList></Reference><Reference><Citation>McMenamin M.E., Nealon J., Lin Y., Wong J.Y., Cheung J.K., Lau E.H.Y., Wu P., Leung G.M., Cowling B.J. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: A population-based observational study. Lancet Infect. Dis. 2022;22:1435&#x2013;1443. doi: 10.1016/S1473-3099(22)00345-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00345-0</ArticleId><ArticleId IdType="pmc">PMC9286709</ArticleId><ArticleId IdType="pubmed">35850128</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J.R., Farber D.L. COVID-19 vaccines: Modes of immune activation and future challenges. Nat. Rev. Immunol. 2021;21:195&#x2013;197. doi: 10.1038/s41577-021-00526-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId><ArticleId IdType="pmc">PMC7934118</ArticleId><ArticleId IdType="pubmed">33674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., Ziogas A., Benn C.S., Giamarellos-Bourboulis E.J., Joosten L.A.B., Arditi M., Chumakov K., van Crevel R., Gallo R., Aaby P., et al. The role of trained immunity in COVID-19: Lessons for the next pandemic. Cell Host Microbe. 2023;31:890&#x2013;901. doi: 10.1016/j.chom.2023.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.05.004</ArticleId><ArticleId IdType="pmc">PMC10265767</ArticleId><ArticleId IdType="pubmed">37321172</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill L.A.J., Netea M.G. BCG-induced trained immunity: Can it offer protection against COVID-19? Nat. Rev. Immunol. 2020;20:335&#x2013;337. doi: 10.1038/s41577-020-0337-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0337-y</ArticleId><ArticleId IdType="pmc">PMC7212510</ArticleId><ArticleId IdType="pubmed">32393823</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K., Avidan M.S., Benn C.S., Bertozzi S.M., Blatt L., Chang A.Y., Jamison D.T., Khader S.A., Kottilil S., Netea M.G., et al. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proc. Natl. Acad. Sci. USA. 2021;118:e2101718118. doi: 10.1073/pnas.2101718118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2101718118</ArticleId><ArticleId IdType="pmc">PMC8166166</ArticleId><ArticleId IdType="pubmed">34006644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang J., Wang M.X., Ang I.Y.H., Tan S.H.X., Lewis R.F., Chen J.I., Gutierrez R.A., Gwee S.X.W., Chua P.E.Y., Yang Q., et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. J. Clin. Med. 2020;9:623. doi: 10.3390/jcm9030623.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030623</ArticleId><ArticleId IdType="pmc">PMC7141113</ArticleId><ArticleId IdType="pubmed">32110875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y.W., Schmitz J.E., Persing D.H., Stratton C.W. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J. Clin. Microbiol. 2020;58:e00512-20. doi: 10.1128/JCM.00512-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00512-20</ArticleId><ArticleId IdType="pmc">PMC7269383</ArticleId><ArticleId IdType="pubmed">32245835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohit E., Rostami Z., Vahidi H. A comparative review of immunoassays for COVID-19 detection. Expert Rev. Clin. Immunol. 2021;17:573&#x2013;599. doi: 10.1080/1744666X.2021.1908886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1908886</ArticleId><ArticleId IdType="pubmed">33787412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi N., Cortade D.L., Ng E., Wang S.X. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens. Bioelectron. 2020;165:112454. doi: 10.1016/j.bios.2020.112454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2020.112454</ArticleId><ArticleId IdType="pmc">PMC7368663</ArticleId><ArticleId IdType="pubmed">32729549</ArticleId></ArticleIdList></Reference><Reference><Citation>Prazuck T., Colin M., Giache S., Gubavu C., Seve A., Rzepecki V., Chevereau-Choquet M., Kiani C., Rodot V., Lionnet E., et al. Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PLoS ONE. 2020;15:e0237694. doi: 10.1371/journal.pone.0237694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237694</ArticleId><ArticleId IdType="pmc">PMC7498027</ArticleId><ArticleId IdType="pubmed">32941461</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan S.D., Patel K.R. Enzyme immunoassay and enzyme-linked immunosorbent assay. J. Investig. Dermatol. 2013;133:e12. doi: 10.1038/jid.2013.287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2013.287</ArticleId><ArticleId IdType="pubmed">23949770</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Barnetche J., Carnalla M., Gaspar-Castillo C., Basto-Abreu A., Lizardi R., Antonio R.A., Martinez I.L., Escamilla A.C., Ramirez O.T., Palomares L.A., et al. Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in Mexico. Sci. Rep. 2022;12:18014. doi: 10.1038/s41598-022-22146-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22146-8</ArticleId><ArticleId IdType="pmc">PMC9606250</ArticleId><ArticleId IdType="pubmed">36289305</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Wang D., Wang H., Zhang X., Liang T., Dai J., Li M., Zhang J., Zhang K., Xu D., et al. COVID-19 diagnostic testing: Technology perspective. Clin. Transl. Med. 2020;10:e158. doi: 10.1002/ctm2.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.158</ArticleId><ArticleId IdType="pmc">PMC7443140</ArticleId><ArticleId IdType="pubmed">32898340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuce M., Filiztekin E., Ozkaya K.G. COVID-19 diagnosis&#x2014;A review of current methods. Biosens. Bioelectron. 2021;172:112752. doi: 10.1016/j.bios.2020.112752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2020.112752</ArticleId><ArticleId IdType="pmc">PMC7584564</ArticleId><ArticleId IdType="pubmed">33126180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong D.S.Y., de Man S.J., Lindeboom F.A., Koeleman J.G.M. Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital. Clin. Microbiol. Infect. 2020;26:1094.e7&#x2013;1094.e10. doi: 10.1016/j.cmi.2020.05.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.05.028</ArticleId><ArticleId IdType="pmc">PMC7265854</ArticleId><ArticleId IdType="pubmed">32502646</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlet J., Petillon C., Ragot E., Abou El Fattah Y., Guillon A., Marchand Adam S., Lemaignen A., Bernard L., Desoubeaux G., Blasco H., et al. Clinical performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective analysis for the diagnosis of COVID-19 in a real-life routine care setting. J. Clin. Virol. 2020;132:104633. doi: 10.1016/j.jcv.2020.104633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104633</ArticleId><ArticleId IdType="pmc">PMC7831733</ArticleId><ArticleId IdType="pubmed">32927357</ArticleId></ArticleIdList></Reference><Reference><Citation>Beavis K.G., Matushek S.M., Abeleda A.P.F., Bethel C., Hunt C., Gillen S., Moran A., Tesic V. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J. Clin. Virol. 2020;129:104468. doi: 10.1016/j.jcv.2020.104468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104468</ArticleId><ArticleId IdType="pmc">PMC7255182</ArticleId><ArticleId IdType="pubmed">32485620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond K.A., Williams E., Nicholson S., Lim S., Johnson D., Cox B., Putland M., Gardiner E., Tippett E., Graham M., et al. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology. 2021;53:773&#x2013;779. doi: 10.1016/j.pathol.2021.05.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2021.05.093</ArticleId><ArticleId IdType="pmc">PMC8289701</ArticleId><ArticleId IdType="pubmed">34412859</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuaillon E., Bollore K., Pisoni A., Debiesse S., Renault C., Marie S., Groc S., Niels C., Pansu N., Dupuy A.M., et al. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J. Infect. 2020;81:e39&#x2013;e45. doi: 10.1016/j.jinf.2020.05.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.077</ArticleId><ArticleId IdType="pmc">PMC7834649</ArticleId><ArticleId IdType="pubmed">32504735</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Elslande J., Houben E., Depypere M., Brackenier A., Desmet S., Andre E., Van Ranst M., Lagrou K., Vermeersch P. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin. Microbiol. Infect. 2020;26:1082&#x2013;1087. doi: 10.1016/j.cmi.2020.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.05.023</ArticleId><ArticleId IdType="pmc">PMC7255746</ArticleId><ArticleId IdType="pubmed">32473953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Zheng Y., Zhang X., Zhang W., Wang D., Jin J., Lin R., Zhang Y., Zhu G., Zhu H., et al. Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. Am. J. Transl. Res. 2020;12:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191168</ArticleId><ArticleId IdType="pubmed">32355546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y., Li Z., Wang K., Li T., Liao P. Performance verification of anti-SARS-CoV-2-specific antibody detection by using four chemiluminescence immunoassay systems. Ann. Clin. Biochem. 2020;57:429&#x2013;434. doi: 10.1177/0004563220963847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0004563220963847</ArticleId><ArticleId IdType="pmc">PMC7672672</ArticleId><ArticleId IdType="pubmed">32961061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli F., Sarasini A., Zierold C., Calleri M., Bonetti A., Vismara C., Blocki F.A., Pallavicini L., Chinali A., Campisi D., et al. Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J. Clin. Microbiol. 2020;58:e01224-20. doi: 10.1128/JCM.01224-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01224-20</ArticleId><ArticleId IdType="pmc">PMC7448652</ArticleId><ArticleId IdType="pubmed">32580948</ArticleId></ArticleIdList></Reference><Reference><Citation>Herroelen P.H., Martens G.A., De Smet D., Swaerts K., Decavele A.S. Humoral Immune Response to SARS-CoV-2. Am. J. Clin. Pathol. 2020;154:610&#x2013;619. doi: 10.1093/ajcp/aqaa140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa140</ArticleId><ArticleId IdType="pmc">PMC7454302</ArticleId><ArticleId IdType="pubmed">32808976</ArticleId></ArticleIdList></Reference><Reference><Citation>Plebani M., Padoan A., Negrini D., Carpinteri B., Sciacovelli L. Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays? Clin. Chim. Acta. 2020;509:1&#x2013;7. doi: 10.1016/j.cca.2020.05.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.05.050</ArticleId><ArticleId IdType="pmc">PMC7261100</ArticleId><ArticleId IdType="pubmed">32485157</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnurra C., Reiners N., Biemann R., Kaiser T., Trawinski H., Jassoy C. Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. J. Clin. Virol. 2020;129:104544. doi: 10.1016/j.jcv.2020.104544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104544</ArticleId><ArticleId IdType="pmc">PMC7836838</ArticleId><ArticleId IdType="pubmed">32663788</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew K.L., Tan S.S., Saw S., Pajarillaga A., Zaine S., Khoo C., Wang W., Tambyah P., Jureen R., Sethi S.K. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clin. Microbiol. Infect. 2020;26:1256.e9&#x2013;1256.e11. doi: 10.1016/j.cmi.2020.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.05.036</ArticleId><ArticleId IdType="pmc">PMC7282795</ArticleId><ArticleId IdType="pubmed">32531475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan A., Pepper G., Wener M.H., Fink S.L., Morishima C., Chaudhary A., Jerome K.R., Mathias P.C., Greninger A.L. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J. Clin. Microbiol. 2020;58:e00941-20. doi: 10.1128/JCM.00941-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00941-20</ArticleId><ArticleId IdType="pmc">PMC7383515</ArticleId><ArticleId IdType="pubmed">32381641</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y., Kurano M., Morita Y., Shimura T., Yokoyama R., Qian C., Xia F., He F., Kishi Y., Okada J., et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci. Rep. 2021;11:2776. doi: 10.1038/s41598-021-82428-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-82428-5</ArticleId><ArticleId IdType="pmc">PMC7854735</ArticleId><ArticleId IdType="pubmed">33531605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Salvagno G.L., Pegoraro M., Militello V., Caloi C., Peretti A., Gaino S., Bassi A., Bovo C., Lo Cascio G. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin. Chem. Lab. Med. 2020;58:1156&#x2013;1159. doi: 10.1515/cclm-2020-0473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0473</ArticleId><ArticleId IdType="pubmed">32301750</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnes J., Sharma P., Berhane S., van Wyk S.S., Nyaaba N., Domen J., Taylor M., Cunningham J., Davenport C., Dittrich S., et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 2022;7:CD013705. doi: 10.1002/14651858.CD013705.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013705.pub3</ArticleId><ArticleId IdType="pmc">PMC9305720</ArticleId><ArticleId IdType="pubmed">35866452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirica A.C., Stan D., Chelcea I.C., Mihailescu C.M., Ofiteru A., Bocancia-Mateescu L.A. Latest Trends in Lateral Flow Immunoassay (LFIA) Detection Labels and Conjugation Process. Front. Bioeng. Biotechnol. 2022;10:922772. doi: 10.3389/fbioe.2022.922772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2022.922772</ArticleId><ArticleId IdType="pmc">PMC9237331</ArticleId><ArticleId IdType="pubmed">35774059</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczula K.M., Gallotta A. Lateral flow assays. Essays Biochem. 2016;60:111&#x2013;120. doi: 10.1042/EBC20150012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20150012</ArticleId><ArticleId IdType="pmc">PMC4986465</ArticleId><ArticleId IdType="pubmed">27365041</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyano A., Serrano-Pertierra E., Salvador M., Martinez-Garcia J.C., Rivas M., Blanco-Lopez M.C. Magnetic Lateral Flow Immunoassays. Diagnostics. 2020;10:288. doi: 10.3390/diagnostics10050288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10050288</ArticleId><ArticleId IdType="pmc">PMC7278001</ArticleId><ArticleId IdType="pubmed">32397264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Miao X., Ma T., Leng Y., Hao L., Duan H., Yuan J., Li Y., Huang X., Xiong Y. Gold Nanobeads with Enhanced Absorbance for Improved Sensitivity in Competitive Lateral Flow Immunoassays. Foods. 2021;10:1488. doi: 10.3390/foods10071488.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods10071488</ArticleId><ArticleId IdType="pmc">PMC8307668</ArticleId><ArticleId IdType="pubmed">34198969</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen S.I., Williams C.T., Garrod G., Fraser A.J., Menzies S., Baldwin L., Brown L., Byrne R.L., Collins A.M., Cubas-Atienzar A.I., et al. Twelve lateral flow immunoassays (LFAs) to detect SARS-CoV-2 antibodies. J. Infect. 2022;84:355&#x2013;360. doi: 10.1016/j.jinf.2021.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.12.007</ArticleId><ArticleId IdType="pmc">PMC8664720</ArticleId><ArticleId IdType="pubmed">34906597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Sakhatskyy P., Chou T.H., Lu S. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV) J. Immunol. Methods. 2005;301:21&#x2013;30. doi: 10.1016/j.jim.2005.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2005.03.008</ArticleId><ArticleId IdType="pmc">PMC7094753</ArticleId><ArticleId IdType="pubmed">15894326</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza E.J., Manguiat K., Wood H., Drebot M. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr. Protoc. Microbiol. 2020;57:ecpmc105. doi: 10.1002/cpmc.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpmc.105</ArticleId><ArticleId IdType="pmc">PMC7300432</ArticleId><ArticleId IdType="pubmed">32475066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohmer N., Westhaus S., Ruhl C., Ciesek S., Rabenau H.F. Clinical performance of different SARS-CoV-2 IgG antibody tests. J. Med. Virol. 2020;92:2243&#x2013;2247. doi: 10.1002/jmv.26145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26145</ArticleId><ArticleId IdType="pmc">PMC7300776</ArticleId><ArticleId IdType="pubmed">32510168</ArticleId></ArticleIdList></Reference><Reference><Citation>Manenti A., Maggetti M., Casa E., Martinuzzi D., Torelli A., Trombetta C.M., Marchi S., Montomoli E. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J. Med. Virol. 2020;92:2096&#x2013;2104. doi: 10.1002/jmv.25986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25986</ArticleId><ArticleId IdType="pmc">PMC7267461</ArticleId><ArticleId IdType="pubmed">32383254</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera R.A., Mok C.K., Tsang O.T., Lv H., Ko R.L., Wu N.C., Yuan M., Leung W.S., Chan J.M., Chik T.S., et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020;25:2000421. doi: 10.2807/1560-7917.ES.2020.25.16.2000421.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.16.2000421</ArticleId><ArticleId IdType="pmc">PMC7189648</ArticleId><ArticleId IdType="pubmed">32347204</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., Zhao C., Hao H., Liu H., Zhang L., Nie L., Qin H., Wang M., et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020;9:680&#x2013;686. doi: 10.1080/22221751.2020.1743767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1743767</ArticleId><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I., Tiu C., Hu Z., Chen V.C., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 2020;38:1073&#x2013;1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson R., Navale G.R., Dharne M.S. Biosensors: Frontiers in rapid detection of COVID-19. 3 Biotech. 2020;10:385. doi: 10.1007/s13205-020-02369-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-020-02369-0</ArticleId><ArticleId IdType="pmc">PMC7417775</ArticleId><ArticleId IdType="pubmed">32818132</ArticleId></ArticleIdList></Reference><Reference><Citation>Drobysh M., Ramanaviciene A., Viter R., Chen C.F., Samukaite-Bubniene U., Ratautaite V., Ramanavicius A. Biosensors for the Determination of SARS-CoV-2 Virus and Diagnosis of COVID-19 Infection. Int. J. Mol. Sci. 2022;23:666. doi: 10.3390/ijms23020666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020666</ArticleId><ArticleId IdType="pmc">PMC8776074</ArticleId><ArticleId IdType="pubmed">35054850</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo G., Lee G., Kim M.J., Baek S.H., Choi M., Ku K.B., Lee C.S., Jun S., Park D., Kim H.G., et al. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. ACS Nano. 2020;14:5135&#x2013;5142. doi: 10.1021/acsnano.0c02823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c02823</ArticleId><ArticleId IdType="pubmed">32293168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo H.T., Wang H.N., Fales A.M., Vo-Dinh T. Plasmonic SERS biosensing nanochips for DNA detection. Anal. Bioanal. Chem. 2016;408:1773&#x2013;1781. doi: 10.1007/s00216-015-9121-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-015-9121-4</ArticleId><ArticleId IdType="pubmed">26547189</ArticleId></ArticleIdList></Reference><Reference><Citation>Soler M., Huertas C.S., Lechuga L.M. Label-free plasmonic biosensors for point-of-care diagnostics: A review. Expert Rev. Mol. Diagn. 2019;19:71&#x2013;81. doi: 10.1080/14737159.2019.1554435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2019.1554435</ArticleId><ArticleId IdType="pubmed">30513011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattab D., Amer M.F.A., Al-Alami Z.M., Bakhtiar A. SARS-CoV-2 journey: From alpha variant to omicron and its sub-variants. Infection. 2024:1&#x2013;20. doi: 10.1007/s15010-024-02223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02223-y</ArticleId><ArticleId IdType="pmc">PMC11143066</ArticleId><ArticleId IdType="pubmed">38554253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Huang Z., Xiao J., Wu Y., Xia N., Yuan Q. Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness. Viruses. 2024;16:184. doi: 10.3390/v16020184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020184</ArticleId><ArticleId IdType="pmc">PMC10893260</ArticleId><ArticleId IdType="pubmed">38399960</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah R., Rais M.A., Mohanty A., Chopra H., Chandran D., Bin Emran T., Dhama K. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world?&#x2013;An overview of current evidence and counteracting strategies. Int. J. Surg. Open. 2023;55:100625. doi: 10.1016/j.ijso.2023.100625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijso.2023.100625</ArticleId><ArticleId IdType="pmc">PMC10192062</ArticleId><ArticleId IdType="pubmed">37255735</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A. COVID-19 Genomics UK (COG-UK) Consortium; et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409&#x2013;424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717&#x2013;726. doi: 10.1038/s41591-021-01294-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01294-w</ArticleId><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Liu Y., Liu J., Zhang X., Zou J., Fontes-Garfias C.R., Xia H., Swanson K.A., Cutler M., Cooper D., et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 2021;27:620&#x2013;621. doi: 10.1038/s41591-021-01270-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01270-4</ArticleId><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Garcia-Knight M.A., Khalid M.M., Servellita V., Wang C., Morris M.K., Sotomayor-Gonzalez A., Glasner D.R., Reyes K.R., Gliwa A.S., et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426&#x2013;3437.e8. doi: 10.1016/j.cell.2021.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.025</ArticleId><ArticleId IdType="pmc">PMC8057738</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J., Gillot C., Cabo J., David C., Dogne J.M., Douxfils J. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster. Int. J. Infect. Dis. 2024;143:107028. doi: 10.1016/j.ijid.2024.107028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2024.107028</ArticleId><ArticleId IdType="pubmed">38583825</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J., Hachmann N.P., Collier A.Y., Lasrado N., Mazurek C.R., Patio R.C., Powers O., Surve N., Theiler J., Korber B., et al. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. N. Engl. J. Med. 2023;388:662&#x2013;664. doi: 10.1056/NEJMc2214314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214314</ArticleId><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., Liu L., Guo Y., Huang Y., Bowen A.D., Liu M., Wang M., Yu J., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279&#x2013;286.e8. doi: 10.1016/j.cell.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Kiso M., Iwatsuki-Horimoto K., Yamayoshi S., Ito M., Chiba S., Sakai-Tagawa Y., Imai M., Kashima Y., Koga M., et al. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 2023;42:113580. doi: 10.1016/j.celrep.2023.113580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113580</ArticleId><ArticleId IdType="pubmed">38103202</ArticleId></ArticleIdList></Reference><Reference><Citation>Looi M.K. COVID-19: Scientists sound alarm over new BA.2.86 &#x201c;Pirola&#x201d; variant. BMJ. 2023;382:1964. doi: 10.1136/bmj.p1964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.p1964</ArticleId><ArticleId IdType="pubmed">37620014</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Jian F., Song W., Yisimayi A., Chen X., Xu Y., Wang P., Wang J., Yu L., et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 2023;23:e457&#x2013;e459. doi: 10.1016/S1473-3099(23)00573-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00573-X</ArticleId><ArticleId IdType="pubmed">37738994</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Xu K., Faraone J.N., Goodarzi N., Zheng Y.M., Carlin C., Bednash J.S., Horowitz J.C., Mallampalli R.K., Saif L.J., et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Cell. 2024;187:585&#x2013;595.e6. doi: 10.1016/j.cell.2023.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.12.026</ArticleId><ArticleId IdType="pmc">PMC10872432</ArticleId><ArticleId IdType="pubmed">38194968</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur S., Sasi S., Pillai S.G., Nag A., Shukla D., Singhal R., Phalke S., Velu G.S.K. SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Front. Med. 2022;9:815389. doi: 10.3389/fmed.2022.815389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.815389</ArticleId><ArticleId IdType="pmc">PMC8902153</ArticleId><ArticleId IdType="pubmed">35273977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascoli C.A. Could mutations of SARS-CoV-2 suppress diagnostic detection? Nat. Biotechnol. 2021;39:274&#x2013;275. doi: 10.1038/s41587-021-00845-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00845-3</ArticleId><ArticleId IdType="pubmed">33603204</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishampel Z.A., Young J., Fischl M., Fischer R.J., Donkor I.O., Riopelle J.C., Schulz J.E., Port J.R., Saturday T.A., van Doremalen N., et al. OraSure InteliSwabTM Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern&#x2014;Alpha, Beta, Gamma, Delta, and Omicron. Viruses. 2022;14:543. doi: 10.3390/v14030543.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030543</ArticleId><ArticleId IdType="pmc">PMC8951130</ArticleId><ArticleId IdType="pubmed">35336950</ArticleId></ArticleIdList></Reference><Reference><Citation>Keam S., Megawati D., Patel S.K., Tiwari R., Dhama K., Harapan H. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. Rev. Med. Virol. 2020;30:e2123. doi: 10.1002/rmv.2123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2123</ArticleId><ArticleId IdType="pmc">PMC7404843</ArticleId><ArticleId IdType="pubmed">32648313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugaraj B., Siriwattananon K., Wangkanont K., Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) Asian Pac. J. Allergy Immunol. 2020;38:10&#x2013;18. doi: 10.12932/AP-200220-0773.</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP-200220-0773</ArticleId><ArticleId IdType="pubmed">32134278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z., Shen C., Peng J. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Viruses. 2023;15:1297. doi: 10.3390/v15061297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15061297</ArticleId><ArticleId IdType="pmc">PMC10302031</ArticleId><ArticleId IdType="pubmed">37376597</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., McConnell S., Casadevall A., Cappello E., Valdiserra G., Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 2022;22:e311&#x2013;e326. doi: 10.1016/S1473-3099(22)00311-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00311-5</ArticleId><ArticleId IdType="pmc">PMC9255948</ArticleId><ArticleId IdType="pubmed">35803289</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew M.N.Y., Kua K.P., Lee S.W.H., Wong K.K. SARS-CoV-2 neutralizing antibody bebtelovimab&#x2013;a systematic scoping review and meta-analysis. Front. Immunol. 2023;14:1100263. doi: 10.3389/fimmu.2023.1100263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1100263</ArticleId><ArticleId IdType="pmc">PMC10494534</ArticleId><ArticleId IdType="pubmed">37701439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T., Hadjadj J., Maes P., Planas D., Seve A., Staropoli I., Guivel-Benhassine F., Porrot F., Bolland W.H., Nguyen Y., et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 2022;28:1297&#x2013;1302. doi: 10.1038/s41591-022-01792-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01792-5</ArticleId><ArticleId IdType="pubmed">35322239</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasoba D., Kosugi Y., Kimura I., Fujita S., Uriu K., Ito J., Sato K. Genotype to Phenotype Japan (G2P-Japan) Consortium. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect. Dis. 2022;22:942&#x2013;943. doi: 10.1016/S1473-3099(22)00365-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00365-6</ArticleId><ArticleId IdType="pmc">PMC9179126</ArticleId><ArticleId IdType="pubmed">35690075</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M., Iwatsuki-Horimoto K., Halfmann P., Watanabe S., Maeda K., et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022;386:1475&#x2013;1477. doi: 10.1056/NEJMc2201933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2201933</ArticleId><ArticleId IdType="pmc">PMC8929374</ArticleId><ArticleId IdType="pubmed">35263535</ArticleId></ArticleIdList></Reference><Reference><Citation>Pochtovyi A.A., Kustova D.D., Siniavin A.E., Dolzhikova I.V., Shidlovskaya E.V., Shpakova O.G., Vasilchenko L.A., Glavatskaya A.A., Kuznetsova N.A., Iliukhina A.A., et al. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1. Vaccines. 2023;11:1533. doi: 10.3390/vaccines11101533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11101533</ArticleId><ArticleId IdType="pmc">PMC10611309</ArticleId><ArticleId IdType="pubmed">37896937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidari A., Sabbatini S., Bastianelli S., Pierucci S., Busti C., Svizzeretto E., Tommasi A., Pallotto C., Schiaroli E., Francisci D. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? Viruses. 2024;16:354. doi: 10.3390/v16030354.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16030354</ArticleId><ArticleId IdType="pmc">PMC10975286</ArticleId><ArticleId IdType="pubmed">38543720</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Das R., Dijokaite-Guraliuc A., Zhou D., Mentzer A.J., Supasa P., Selvaraj M., Duyvesteyn H.M.E., Ritter T.G., Temperton N., et al. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection. Nat. Commun. 2024;15:3284. doi: 10.1038/s41467-024-47393-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47393-3</ArticleId><ArticleId IdType="pmc">PMC11021415</ArticleId><ArticleId IdType="pubmed">38627386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Gerosa M., Bellocchi C., Arroyo-Sanchez D., Asperti C., Argolini L.M., Gallina G., Cornalba M., Scotti I., Suardi I., et al. Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study. Biomolecules. 2023;13:1273. doi: 10.3390/biom13091273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13091273</ArticleId><ArticleId IdType="pmc">PMC10527378</ArticleId><ArticleId IdType="pubmed">37759674</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha L.B., Tedla N., Bull R.A. Broadly-Neutralizing Antibodies against Emerging SARS-CoV-2 Variants. Front. Immunol. 2021;12:752003. doi: 10.3389/fimmu.2021.752003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.752003</ArticleId><ArticleId IdType="pmc">PMC8502962</ArticleId><ArticleId IdType="pubmed">34646276</ArticleId></ArticleIdList></Reference><Reference><Citation>Widyasari K., Kim J. A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19) Antibodies. 2023;12:5. doi: 10.3390/antib12010005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib12010005</ArticleId><ArticleId IdType="pmc">PMC9887598</ArticleId><ArticleId IdType="pubmed">36648889</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., Aschenbrenner A.C. COVID-19 and the human innate immune system. Cell. 2021;184:1671&#x2013;1692. doi: 10.1016/j.cell.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu R.J., Yu W.C., Peng G.R., Ye C.H., Hu S., Chong P.C.T., Yap K.Y., Lee J.Y.C., Lin W.C., Yu S.H. The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Front. Immunol. 2022;13:832394. doi: 10.3389/fimmu.2022.832394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.832394</ArticleId><ArticleId IdType="pmc">PMC9021400</ArticleId><ArticleId IdType="pubmed">35464491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C., Wang Y., Hu M., Wen L., Wen C., Wang Y., Zhu W., Tai S., Jiang Z., Xiao K., et al. Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin. Transl. Immunol. 2020;9:e1182. doi: 10.1002/cti2.1182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1182</ArticleId><ArticleId IdType="pmc">PMC7519951</ArticleId><ArticleId IdType="pubmed">33005417</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861&#x2013;880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A., Chauhan P., Saha B., Jafarzadeh S., Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102. doi: 10.1016/j.lfs.2020.118102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118102</ArticleId><ArticleId IdType="pmc">PMC7367812</ArticleId><ArticleId IdType="pubmed">32687918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., To K.K., Wong Y.C., Liu L., Zhou B., Li X., Huang H., Mo Y., Luk T.Y., Lau T.T., et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020;53:864&#x2013;877.e5. doi: 10.1016/j.immuni.2020.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.07.026</ArticleId><ArticleId IdType="pmc">PMC7402670</ArticleId><ArticleId IdType="pubmed">32791036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota S., Miyamae T., Kuroiwa Y., Nishioka K. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology. J. Clin. Med. 2021;10:801. doi: 10.3390/jcm10040801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10040801</ArticleId><ArticleId IdType="pmc">PMC7922214</ArticleId><ArticleId IdType="pubmed">33671159</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Haurum J.S. Recombinant polyclonal antibodies: The next generation of antibody therapeutics? Drug Discov. Today. 2006;11:655&#x2013;660. doi: 10.1016/j.drudis.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2006.05.009</ArticleId><ArticleId IdType="pubmed">16793535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M.G., Zhang Z., Gao Q., Pan M., Rowan E.G., Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: An overview. Immunol. Res. 2020;68:325&#x2013;339. doi: 10.1007/s12026-020-09159-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-020-09159-z</ArticleId><ArticleId IdType="pmc">PMC7648849</ArticleId><ArticleId IdType="pubmed">33161557</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., Pirofski L.A. The convalescent sera option for containing COVID-19. J. Clin. Investig. 2020;130:1545&#x2013;1548. doi: 10.1172/JCI138003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138003</ArticleId><ArticleId IdType="pmc">PMC7108922</ArticleId><ArticleId IdType="pubmed">32167489</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Wong R., Soo Y.O., Wong W.S., Lee C.K., Ng M.H., Chan P., Wong K.C., Leung C.B., Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 2005;24:44&#x2013;46. doi: 10.1007/s10096-004-1271-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-004-1271-9</ArticleId><ArticleId IdType="pmc">PMC7088355</ArticleId><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung I.F., To K.K., Lee C.K., Lee K.L., Chan K., Yan W.W., Liu R., Watt C.L., Chan W.M., Lai K.Y., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 2011;52:447&#x2013;456. doi: 10.1093/cid/ciq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq106</ArticleId><ArticleId IdType="pmc">PMC7531589</ArticleId><ArticleId IdType="pubmed">21248066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahr F., Ansumana R., Massaquoi T.A., Idriss B.R., Sesay F.R., Lamin J.M., Baker S., Nicol S., Conton B., Johnson W., et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J. Infect. 2017;74:302&#x2013;309. doi: 10.1016/j.jinf.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2016.11.009</ArticleId><ArticleId IdType="pmc">PMC7112610</ArticleId><ArticleId IdType="pubmed">27867062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Sharma V., Priya K. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy. Am. J. Emerg. Med. 2021;41:244&#x2013;246. doi: 10.1016/j.ajem.2020.05.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.05.101</ArticleId><ArticleId IdType="pmc">PMC7265850</ArticleId><ArticleId IdType="pubmed">32505474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020;20:398&#x2013;400. doi: 10.1016/S1473-3099(20)30141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30141-9</ArticleId><ArticleId IdType="pmc">PMC7128218</ArticleId><ArticleId IdType="pubmed">32113510</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Zhang W., Hu Y., Tong X., Zheng S., Yang J., Kong Y., Ren L., Wei Q., Mei H., et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:460&#x2013;470. doi: 10.1001/jama.2020.10044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10044</ArticleId><ArticleId IdType="pmc">PMC7270883</ArticleId><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>Misset B., Piagnerelli M., Hoste E., Dardenne N., Grimaldi D., Michaux I., De Waele E., Dumoulin A., Jorens P.G., van der Hauwaert E., et al. Convalescent Plasma for COVID-19-Induced ARDS in Mechanically Ventilated Patients. N. Engl. J. Med. 2023;389:1590&#x2013;1600. doi: 10.1056/NEJMoa2209502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209502</ArticleId><ArticleId IdType="pmc">PMC10755833</ArticleId><ArticleId IdType="pubmed">37889107</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvin A.M., Fink K., Schmid M.A., Cathcart A., Spreafico R., Havenar-Daughton C., Lanzavecchia A., Corti D., Virgin H.W. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584:353&#x2013;363. doi: 10.1038/s41586-020-2538-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2538-8</ArticleId><ArticleId IdType="pubmed">32659783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S., Uddin S.M., Ali A., Anjum F., Ali R., Shalim E., Khan M., Ahmed I., Muhaymin S.M., Bukhari U., et al. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy. 2021;13:397&#x2013;407. doi: 10.2217/imt-2020-0263.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2020-0263</ArticleId><ArticleId IdType="pmc">PMC7871744</ArticleId><ArticleId IdType="pubmed">33557591</ArticleId></ArticleIdList></Reference><Reference><Citation>Perricone C., Triggianese P., Bursi R., Cafaro G., Bartoloni E., Chimenti M.S., Gerli R., Perricone R. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. Microorganisms. 2021;9:121. doi: 10.3390/microorganisms9010121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9010121</ArticleId><ArticleId IdType="pmc">PMC7825648</ArticleId><ArticleId IdType="pubmed">33430200</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M.A., Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 2000;13:602&#x2013;614. doi: 10.1128/CMR.13.4.602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.13.4.602</ArticleId><ArticleId IdType="pmc">PMC88952</ArticleId><ArticleId IdType="pubmed">11023960</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor Y., Shinar E., Izak M., Rahav G., Brosh-Nissimov T., Kessler A., Rahimi-Levene N., Benin-Goren O., Cohen D., Zohar I., et al. A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients with Coronavirus 2019. Clin. Infect. Dis. 2023;77:964&#x2013;971. doi: 10.1093/cid/ciad305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad305</ArticleId><ArticleId IdType="pmc">PMC10552585</ArticleId><ArticleId IdType="pubmed">37220751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D., Li Y.F., Liang H., Wu J.Z., Hu Y., Peng Y., Li T.J., Hou J.F., Huang W.J., Guan L.D., et al. Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma. Adv. Sci. 2022;9:e2104333. doi: 10.1002/advs.202104333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202104333</ArticleId><ArticleId IdType="pmc">PMC9108634</ArticleId><ArticleId IdType="pubmed">35403837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahra F.T., Bellusci L., Grubbs G., Golding H., Khurana S. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19. Ann. Rheum. Dis. 2022;81:1044&#x2013;1045. doi: 10.1136/annrheumdis-2022-222115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222115</ArticleId><ArticleId IdType="pubmed">35144925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann M.F., Mohsen M.O., Zha L., Vogel M., Speiser D.E. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines. 2021;6:2. doi: 10.1038/s41541-020-00264-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00264-6</ArticleId><ArticleId IdType="pmc">PMC7782831</ArticleId><ArticleId IdType="pubmed">33398006</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebe E.C., Dejenie T.A. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front. Immunol. 2023;14:1055457. doi: 10.3389/fimmu.2023.1055457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055457</ArticleId><ArticleId IdType="pmc">PMC9892939</ArticleId><ArticleId IdType="pubmed">36742320</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro Dopico X., Ols S., Lore K., Karlsson Hedestam G.B. Immunity to SARS-CoV-2 induced by infection or vaccination. J. Intern. Med. 2022;291:32&#x2013;50. doi: 10.1111/joim.13372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13372</ArticleId><ArticleId IdType="pmc">PMC8447342</ArticleId><ArticleId IdType="pubmed">34352148</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H., Vanshylla K., Weber T., Barnes C.O., Kreer C., Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022;55:925&#x2013;944. doi: 10.1016/j.immuni.2022.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.05.005</ArticleId><ArticleId IdType="pmc">PMC9118976</ArticleId><ArticleId IdType="pubmed">35623355</ArticleId></ArticleIdList></Reference><Reference><Citation>Galipeau Y., Greig M., Liu G., Driedger M., Langlois M.A. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front. Immunol. 2020;11:610688. doi: 10.3389/fimmu.2020.610688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.610688</ArticleId><ArticleId IdType="pmc">PMC7775512</ArticleId><ArticleId IdType="pubmed">33391281</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., Astudillo M.G., Yang D., Miller T.E., Feldman J., Hauser B.M., Caradonna T.M., Clayton K.L., Nitido A.D., et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476&#x2013;488.e11. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205&#x2013;1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Steain M., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Kent S.J., Triccas J.A., Khoury D.S., Davenport M.P. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe. 2022;3:e52&#x2013;e61. doi: 10.1016/S2666-5247(21)00267-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00267-6</ArticleId><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Steain M., Reynaldi A., Schlub T.E., Khan S.R., Sasson S.C., Kent S.J., Khoury D.S., Davenport M.P. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: A meta-analysis. Nat. Commun. 2023;14:1633. doi: 10.1038/s41467-023-37176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37176-7</ArticleId><ArticleId IdType="pmc">PMC10036966</ArticleId><ArticleId IdType="pubmed">36964146</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry J., Osman S., Wright J., Richard-Greenblatt M., Buchan S.A., Sadarangani M., Bolotin S. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS ONE. 2022;17:e0266852. doi: 10.1371/journal.pone.0266852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266852</ArticleId><ArticleId IdType="pmc">PMC8993021</ArticleId><ArticleId IdType="pubmed">35395052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G., Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int. J. Biol. Sci. 2020;16:1718&#x2013;1723. doi: 10.7150/ijbs.45123.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.45123</ArticleId><ArticleId IdType="pmc">PMC7098029</ArticleId><ArticleId IdType="pubmed">32226289</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Ma Q., Ren J., Guo W., Feng K., Li Z., Huang T., Cai Y.D. Immune responses of different COVID-19 vaccination strategies by analyzing single-cell RNA sequencing data from multiple tissues using machine learning methods. Front. Genet. 2023;14:1157305. doi: 10.3389/fgene.2023.1157305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2023.1157305</ArticleId><ArticleId IdType="pmc">PMC10065150</ArticleId><ArticleId IdType="pubmed">37007947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyanathan M., Afkhami S., Smaill F., Miller M.S., Lichty B.D., Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615&#x2013;632. doi: 10.1038/s41577-020-00434-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00434-6</ArticleId><ArticleId IdType="pmc">PMC7472682</ArticleId><ArticleId IdType="pubmed">32887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A., Aguirre-Sampieri S., Sampieri A., Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Front. Immunol. 2021;12:701501. doi: 10.3389/fimmu.2021.701501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.701501</ArticleId><ArticleId IdType="pmc">PMC8311925</ArticleId><ArticleId IdType="pubmed">34322129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakidis N.C., Lopez-Cortes A., Gonzalez E.V., Grimaldos A.B., Prado E.O. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28. doi: 10.1038/s41541-021-00292-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00292-w</ArticleId><ArticleId IdType="pmc">PMC7900244</ArticleId><ArticleId IdType="pubmed">33619260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Bhattacharya M., Dhama K. SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. Vaccines. 2023;11:682. doi: 10.3390/vaccines11030682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030682</ArticleId><ArticleId IdType="pmc">PMC10054865</ArticleId><ArticleId IdType="pubmed">36992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cardenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates T.A., McBride S.K., Leier H.C., Guzman G., Lyski Z.L., Schoen D., Winders B., Lee J.Y., Lee D.X., Messer W.B., et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci. Immunol. 2022;7:eabn8014. doi: 10.1126/sciimmunol.abn8014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abn8014</ArticleId><ArticleId IdType="pmc">PMC8939472</ArticleId><ArticleId IdType="pubmed">35076258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaeck L.M., GeurtsvanKessel C.H., de Vries R.D. COVID-19 vaccine effectiveness and evolving variants: Understanding the immunological footprint. Lancet Respir. Med. 2023;11:395&#x2013;396. doi: 10.1016/S2213-2600(23)00140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00140-6</ArticleId><ArticleId IdType="pmc">PMC10109542</ArticleId><ArticleId IdType="pubmed">37080227</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021;397:881&#x2013;891. doi: 10.1016/S0140-6736(21)00432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00432-3</ArticleId><ArticleId IdType="pmc">PMC7894131</ArticleId><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:2032&#x2013;2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43&#x2013;50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O&#x2019;Connell A.M., et al. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386:1532&#x2013;1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Alter G., Crotty S., Plotkin S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022;310:6&#x2013;26. doi: 10.1111/imr.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13091</ArticleId><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle K.A., Ambrosino D.M., Fiore-Gartland A., Goldblatt D., Gilbert P.B., Siber G.R., Dull P., Plotkin S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423&#x2013;4428. doi: 10.1016/j.vaccine.2021.05.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.063</ArticleId><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Follmann D., O&#x2019;Brien M.P., Fintzi J., Fay M.P., Montefiori D., Mateja A., Herman G.A., Hooper A.T., Turner K.C., Chan K.C., et al. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat. Commun. 2023;14:3605. doi: 10.1038/s41467-023-39292-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39292-w</ArticleId><ArticleId IdType="pmc">PMC10276829</ArticleId><ArticleId IdType="pubmed">37330602</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen K., Boyd S.D. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. 2021;29:1063&#x2013;1075. doi: 10.1016/j.chom.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8233571</ArticleId><ArticleId IdType="pubmed">34174992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A., Yu J., McMahan K., Jacob-Dolan C., Liu J., He X., Hope D., Anioke T., Barrett J., Chung B., et al. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell. 2022;185:1549&#x2013;1555.e11. doi: 10.1016/j.cell.2022.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.024</ArticleId><ArticleId IdType="pmc">PMC8926910</ArticleId><ArticleId IdType="pubmed">35427477</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Yu J., McMahan K., Jacob-Dolan C., He X., Giffin V., Wu C., Sciacca M., Powers O., Nampanya F., et al. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. Sci. Immunol. 2022;7:eabq7647. doi: 10.1126/sciimmunol.abq7647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq7647</ArticleId><ArticleId IdType="pmc">PMC9407944</ArticleId><ArticleId IdType="pubmed">35943359</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Polidori L., Antonelli M., Penamakuri S., Nogal A., Louca P., May A., Figueiredo J.C., Hu C., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618&#x2013;1624. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Jackson C.B., Mou H., Ojha A., Peng H., Quinlan B.D., Rangarajan E.S., Pan A., Vanderheiden A., Suthar M.S., et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 2020;11:6013. doi: 10.1038/s41467-020-19808-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19808-4</ArticleId><ArticleId IdType="pmc">PMC7693302</ArticleId><ArticleId IdType="pubmed">33243994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozono S., Zhang Y., Ode H., Sano K., Tan T.S., Imai K., Miyoshi K., Kishigami S., Ueno T., Iwatani Y., et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 2021;12:848. doi: 10.1038/s41467-021-21118-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21118-2</ArticleId><ArticleId IdType="pmc">PMC7870668</ArticleId><ArticleId IdType="pubmed">33558493</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Hilton S.K., Ellis D., Crawford K.H.D., Dingens A.S., Navarro M.J., Bowen J.E., Tortorici M.A., Walls A.C., et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020;182:1295&#x2013;1310.e20. doi: 10.1016/j.cell.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabino E.C., Buss L.F., Carvalho M.P.S., Prete C.A., Jr., Crispim M.A.E., Fraiji N.A., Pereira R.H.M., Parag K.V., da Silva Peixoto P., Kraemer M.U.G., et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397:452&#x2013;455. doi: 10.1016/S0140-6736(21)00183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00183-5</ArticleId><ArticleId IdType="pmc">PMC7906746</ArticleId><ArticleId IdType="pubmed">33515491</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F., Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T., et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. 2021;26:2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.24.2100509</ArticleId><ArticleId IdType="pmc">PMC8212592</ArticleId><ArticleId IdType="pubmed">34142653</ArticleId></ArticleIdList></Reference><Reference><Citation>Emary K.R.W., Golubchik T., Aley P.K., Ariani C.V., Angus B., Bibi S., Blane B., Bonsall D., Cicconi P., Charlton S., et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351&#x2013;1362. doi: 10.1016/S0140-6736(21)00628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00628-0</ArticleId><ArticleId IdType="pmc">PMC8009612</ArticleId><ArticleId IdType="pubmed">33798499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cardenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Van Dromme I., Spiessens B., et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N. Engl. J. Med. 2022;386:847&#x2013;860. doi: 10.1056/NEJMoa2117608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117608</ArticleId><ArticleId IdType="pmc">PMC8849184</ArticleId><ArticleId IdType="pubmed">35139271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao W., Chen X., Zheng C., Liu H., Wang G., Zhang B., Li Z., Zhang W. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: A literature review and meta-analysis. Emerg. Microbes Infect. 2022;11:2383&#x2013;2392. doi: 10.1080/22221751.2022.2122582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2122582</ArticleId><ArticleId IdType="pmc">PMC9542696</ArticleId><ArticleId IdType="pubmed">36069511</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis-Gardner M.E., Lai L., Wali B., Samaha H., Solis D., Lee M., Porter-Morrison A., Hentenaar I.T., Yamamoto F., Godbole S., et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N. Engl. J. Med. 2023;388:183&#x2013;185. doi: 10.1056/NEJMc2214293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214293</ArticleId><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>Winokur P., Gayed J., Fitz-Patrick D., Thomas S.J., Diya O., Lockhart S., Xu X., Zhang Y., Bangad V., Schwartz H.I., et al. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years. N. Engl. J. Med. 2023;388:214&#x2013;227. doi: 10.1056/NEJMoa2213082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2213082</ArticleId><ArticleId IdType="pmc">PMC9933930</ArticleId><ArticleId IdType="pubmed">36652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.Y., Xu Y., Gu Y., Zeng D., Wheeler B., Young H., Sunny S.K., Moore Z. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N. Engl. J. Med. 2023;388:764&#x2013;766. doi: 10.1056/NEJMc2215471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2215471</ArticleId><ArticleId IdType="pmc">PMC9933929</ArticleId><ArticleId IdType="pubmed">36734847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateo-Urdiales A., Sacco C., Fotakis E.A., Del Manso M., Bella A., Riccardo F., Bressi M., Rota M.C., Petrone D., Siddu A., et al. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: A retrospective matched cohort study. Lancet Infect. Dis. 2023;23:1349&#x2013;1359. doi: 10.1016/S1473-3099(23)00374-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00374-2</ArticleId><ArticleId IdType="pubmed">37478877</ArticleId></ArticleIdList></Reference><Reference><Citation>Trombetta C.M., Piccini G., Pierleoni G., Leonardi M., Dapporto F., Marchi S., Andreano E., Paciello I., Benincasa L., Lovreglio P., et al. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations. Commun. Biol. 2022;5:903. doi: 10.1038/s42003-022-03849-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03849-0</ArticleId><ArticleId IdType="pmc">PMC9439265</ArticleId><ArticleId IdType="pubmed">36056181</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K., Ito J., Zahradnik J., Fujita S., Kosugi Y., Schreiber G. Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato, K. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect. Dis. 2023;23:280&#x2013;281. doi: 10.1016/S1473-3099(23)00051-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00051-8</ArticleId><ArticleId IdType="pmc">PMC9889095</ArticleId><ArticleId IdType="pubmed">36736338</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinholm A., Maljanen S., Jalkanen P., Altan E., Tauriainen S., Belik M., Skon M., Haveri A., Osterlund P., Iakubovskaia A., et al. Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection. Commun. Med. 2024;4:28. doi: 10.1038/s43856-024-00457-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-024-00457-3</ArticleId><ArticleId IdType="pmc">PMC10891120</ArticleId><ArticleId IdType="pubmed">38396065</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A.S., Tao X., Algaissi A., Garron T., Narayanan K., Peng B.H., Couch R.B., Tseng C.T. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccines Immunother. 2016;12:2351&#x2013;2356. doi: 10.1080/21645515.2016.1177688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1177688</ArticleId><ArticleId IdType="pmc">PMC5027702</ArticleId><ArticleId IdType="pubmed">27269431</ArticleId></ArticleIdList></Reference><Reference><Citation>Stettler K., Beltramello M., Espinosa D.A., Graham V., Cassotta A., Bianchi S., Vanzetta F., Minola A., Jaconi S., Mele F., et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353:823&#x2013;826. doi: 10.1126/science.aaf8505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8505</ArticleId><ArticleId IdType="pubmed">27417494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Wei Q., Lin Q., Fang J., Wang H., Kwok H., Tang H., Nishiura K., Peng J., Tan Z., et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4:e123158. doi: 10.1172/jci.insight.123158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123158</ArticleId><ArticleId IdType="pmc">PMC6478436</ArticleId><ArticleId IdType="pubmed">30830861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziganshina M.M., Shilova N.V., Khalturina E.O., Dolgushina N.V., Borisevich S.V., Yarotskaya E.L., Bovin N.V., Sukhikh G.T. Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies. Viruses. 2023;15:1584. doi: 10.3390/v15071584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071584</ArticleId><ArticleId IdType="pmc">PMC10384250</ArticleId><ArticleId IdType="pubmed">37515270</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W.S., Wheatley A.K., Kent S.J., DeKosky B.J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 2020;5:1185&#x2013;1191. doi: 10.1038/s41564-020-00789-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00789-5</ArticleId><ArticleId IdType="pubmed">32908214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetro J.A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22:72&#x2013;73. doi: 10.1016/j.micinf.2020.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.02.006</ArticleId><ArticleId IdType="pmc">PMC7102551</ArticleId><ArticleId IdType="pubmed">32092539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wang J., Yu X., Jiang W., Chen S., Wang R., Wang M., Jiao S., Yang Y., Wang W., et al. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcgammaRIIB and virus-antibody complex with bivalent interaction. Commun. Biol. 2022;5:262. doi: 10.1038/s42003-022-03207-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03207-0</ArticleId><ArticleId IdType="pmc">PMC8948278</ArticleId><ArticleId IdType="pubmed">35332252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohdatsu T., Yamada M., Tominaga R., Makino K., Kida K., Koyama H. Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J. Vet. Med. Sci. 1998;60:49&#x2013;55. doi: 10.1292/jvms.60.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.60.49</ArticleId><ArticleId IdType="pubmed">9492360</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaume M., Yip M.S., Cheung C.Y., Leung H.L., Li P.H., Kien F., Dutry I., Callendret B., Escriou N., Altmeyer R., et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J. Virol. 2011;85:10582&#x2013;10597. doi: 10.1128/JVI.00671-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00671-11</ArticleId><ArticleId IdType="pmc">PMC3187504</ArticleId><ArticleId IdType="pubmed">21775467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam Y.W., Kien F., Roberts A., Cheung Y.C., Lamirande E.W., Vogel L., Chu S.L., Tse J., Guarner J., Zaki S.R., et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007;25:729&#x2013;740. doi: 10.1016/j.vaccine.2006.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.08.011</ArticleId><ArticleId IdType="pmc">PMC7115629</ArticleId><ArticleId IdType="pubmed">17049691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijkers G.T., van Overveld F.J. The &#x201c;original antigenic sin&#x201d; and its relevance for SARS-CoV-2 (COVID-19) vaccination. Clin. Immunol. Commun. 2021;1:13&#x2013;16. doi: 10.1016/j.clicom.2021.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clicom.2021.10.001</ArticleId><ArticleId IdType="pmc">PMC8500682</ArticleId><ArticleId IdType="pubmed">38620690</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Barrett J., He X. Immune Imprinting and Implications for COVID-19. Vaccines. 2023;11:875. doi: 10.3390/vaccines11040875.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040875</ArticleId><ArticleId IdType="pmc">PMC10142218</ArticleId><ArticleId IdType="pubmed">37112787</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen K., Nielsen S.C.A., Silva O., Younes S.F., Zaslavsky M., Costales C., Yang F., Wirz O.F., Solis D., Hoh R.A., et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025&#x2013;1040.e14. doi: 10.1016/j.cell.2022.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusnik J., Zorn J., Monzon-Posadas W.O., Peters K., Osypchuk E., Blaschke S., Streeck H. Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin. Nat. Commun. 2024;15:3102. doi: 10.1038/s41467-024-47451-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47451-w</ArticleId><ArticleId IdType="pmc">PMC11006949</ArticleId><ArticleId IdType="pubmed">38600072</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E., Gavriatopoulou M., Hicklen R.S., Ntanasis-Stathopoulos I., Kastritis E., Fotiou D., Stamatelopoulos K., Terpos E., Kotanidou A., Hagberg C.A., et al. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J. Infect. 2021;83:1&#x2013;16. doi: 10.1016/j.jinf.2021.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8118709</ArticleId><ArticleId IdType="pubmed">33992686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohata T. Neuro-COVID-19. Clin. Exp. Neuroimmunol. 2022;13:17&#x2013;23. doi: 10.1111/cen3.12676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen3.12676</ArticleId><ArticleId IdType="pmc">PMC8652810</ArticleId><ArticleId IdType="pubmed">34899999</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Bruggen M.C., O&#x2019;Mahony L., Gao Y., Nadeau K., Akdis C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564&#x2013;1581. doi: 10.1111/all.14364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14364</ArticleId><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Poh C.M., Renia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020;20:363&#x2013;374. doi: 10.1038/s41577-020-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sewell H.F., Agius R.M., Stewart M., Kendrick D. Cellular immune responses to COVID-19. BMJ. 2020;370:m3018. doi: 10.1136/bmj.m3018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3018</ArticleId><ArticleId IdType="pubmed">32737031</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., Horn C., Vanshylla K., Cristanziano V.D., Osebold L., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: A longitudinal prospective cohort study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rank A., Tzortzini A., Kling E., Schmid C., Claus R., Loll E., Burger R., Rommele C., Dhillon C., Muller K., et al. One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms. J. Clin. Med. 2021;10:3305. doi: 10.3390/jcm10153305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10153305</ArticleId><ArticleId IdType="pmc">PMC8347559</ArticleId><ArticleId IdType="pubmed">34362088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Etayo F.J., Suarez-Fernandez P., Cabrera-Marante O., Arroyo D., Garcinuno S., Naranjo L., Pleguezuelo D.E., Allende L.M., Mancebo E., Lalueza A., et al. T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. Front. Cell Infect. Microbiol. 2021;11:624483. doi: 10.3389/fcimb.2021.624483.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.624483</ArticleId><ArticleId IdType="pmc">PMC7952877</ArticleId><ArticleId IdType="pubmed">33718270</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A.E., Ramirez J.D., Delgado-Noguera L.A., Rodriguez-Morales A.J., Sordillo E.M. COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm. PLoS Negl. Trop. Dis. 2021;15:e0009402. doi: 10.1371/journal.pntd.0009402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0009402</ArticleId><ArticleId IdType="pmc">PMC8143422</ArticleId><ArticleId IdType="pubmed">34029332</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S., Fishell G. In SARS-CoV-2, astrocytes are in it for the long haul. Proc. Natl. Acad. Sci. USA. 2022;119:e2209130119. doi: 10.1073/pnas.2209130119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2209130119</ArticleId><ArticleId IdType="pmc">PMC9335203</ArticleId><ArticleId IdType="pubmed">35858460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirzel C., Grandgirard D., Surial B., Wider M.F., Leppert D., Kuhle J., Walti L.N., Schefold J.C., Spinetti T., Suter-Riniker F., et al. Neuro-axonal injury in COVID-19: The role of systemic inflammation and SARS-CoV-2 specific immune response. Ther. Adv. Neurol. Disord. 2022;15:17562864221080528. doi: 10.1177/17562864221080528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864221080528</ArticleId><ArticleId IdType="pmc">PMC8922213</ArticleId><ArticleId IdType="pubmed">35299779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L., Dai L., Zhang Y., Fu W., Gao Y., Zhang Z., Zhang Z. Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients with Coronavirus Disease 2019 in Wuhan, China. Front. Med. 2020;7:532. doi: 10.3389/fmed.2020.00532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00532</ArticleId><ArticleId IdType="pmc">PMC7438719</ArticleId><ArticleId IdType="pubmed">32903644</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q., Yang Y., Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56:102799. doi: 10.1016/j.ebiom.2020.102799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102799</ArticleId><ArticleId IdType="pmc">PMC7255711</ArticleId><ArticleId IdType="pubmed">32474399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Espindola O.M., Siqueira M., Soares C.N., Lima M., Leite A., Araujo A.Q.C., Brandao C.O., Silva M.T.T. Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid. Int. J. Infect. Dis. 2020;96:567&#x2013;569. doi: 10.1016/j.ijid.2020.05.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.123</ArticleId><ArticleId IdType="pmc">PMC7271861</ArticleId><ArticleId IdType="pubmed">32505878</ArticleId></ArticleIdList></Reference><Reference><Citation>Heming M., Li X., Rauber S., Mausberg A.K., Borsch A.L., Hartlehnert M., Singhal A., Lu I.N., Fleischer M., Szepanowski F., et al. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity. 2021;54:164&#x2013;175.e6. doi: 10.1016/j.immuni.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7831653</ArticleId><ArticleId IdType="pubmed">33382973</ArticleId></ArticleIdList></Reference><Reference><Citation>Remsik J., Wilcox J.A., Babady N.E., McMillen T.A., Vachha B.A., Halpern N.A., Dhawan V., Rosenblum M., Iacobuzio-Donahue C.A., Avila E.K., et al. Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. Cancer Cell. 2021;39:276&#x2013;283.e3. doi: 10.1016/j.ccell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7833316</ArticleId><ArticleId IdType="pubmed">33508216</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin P., Collongues N., Baloglu S., Bedo D., Bassand X., Lavaux T., Gautier-Vargas G., Keller N., Kremer S., Fafi-Kremer S., et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur. J. Neurol. 2021;28:248&#x2013;258. doi: 10.1111/ene.14491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14491</ArticleId><ArticleId IdType="pmc">PMC7461405</ArticleId><ArticleId IdType="pubmed">32853434</ArticleId></ArticleIdList></Reference><Reference><Citation>Charnley M., Islam S., Bindra G.K., Engwirda J., Ratcliffe J., Zhou J., Mezzenga R., Hulett M.D., Han K., Berryman J.T., et al. Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: Potential implications for neurological symptoms in COVID-19. Nat. Commun. 2022;13:3387. doi: 10.1038/s41467-022-30932-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30932-1</ArticleId><ArticleId IdType="pmc">PMC9189797</ArticleId><ArticleId IdType="pubmed">35697699</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystrom S., Hammarstrom P. Amyloidogenesis of SARS-CoV-2 Spike Protein. J. Am. Chem. Soc. 2022;144:8945&#x2013;8950. doi: 10.1021/jacs.2c03925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c03925</ArticleId><ArticleId IdType="pmc">PMC9136918</ArticleId><ArticleId IdType="pubmed">35579205</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C.W., Sun J., Dickey J.M., Ylaya K., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Sillett R., Zhu L., Mendel J., Camplisson I., Dercon Q., Harrison P.J. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1,284,437 patients. Lancet Psychiatry. 2022;9:815&#x2013;827. doi: 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrees D., Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration. Biochem. Biophys. Res. Commun. 2021;554:94&#x2013;98. doi: 10.1016/j.bbrc.2021.03.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.03.100</ArticleId><ArticleId IdType="pmc">PMC7988450</ArticleId><ArticleId IdType="pubmed">33789211</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J.R., Dhodapkar R.M., Lu P., Gehlhausen J.R., Tabachnikova A., Greene K., Tabacof L., Malik A.A., et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623:139&#x2013;148. doi: 10.1038/s41586-023-06651-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Emeribe A.U., Abdullahi I.N., Shuwa H.A., Uzairue L., Musa S., Anka A.U., Adekola H.A., Bello Z.M., Rogo L.D., Aliyu D., et al. Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: An analysis of global reports. Int Health. 2022;14:18&#x2013;52. doi: 10.1093/inthealth/ihab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/inthealth/ihab005</ArticleId><ArticleId IdType="pmc">PMC7928871</ArticleId><ArticleId IdType="pubmed">33620427</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti D., Purcell L.A., Snell G., Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184:3086&#x2013;3108. doi: 10.1016/j.cell.2021.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.005</ArticleId><ArticleId IdType="pmc">PMC8152891</ArticleId><ArticleId IdType="pubmed">34087172</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Ito M., Kiso M., Yamayoshi S., Iwatsuki-Horimoto K., Furusawa Y., Sakai-Tagawa Y., Imai M., Koga M., Yamamoto S., et al. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect. Dis. 2023;23:402&#x2013;403. doi: 10.1016/S1473-3099(23)00070-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00070-1</ArticleId><ArticleId IdType="pmc">PMC9908083</ArticleId><ArticleId IdType="pubmed">36773622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameroni E., Bowen J.E., Rosen L.E., Saliba C., Zepeda S.K., Culap K., Pinto D., VanBlargan L.A., De Marco A., di Iulio J., et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602:664&#x2013;670. doi: 10.1038/s41586-021-04386-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04386-2</ArticleId><ArticleId IdType="pmc">PMC9531318</ArticleId><ArticleId IdType="pubmed">35016195</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.H., Porrot F., Staropoli I., Lemoine F., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671&#x2013;675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Jr., Purcell L.A., Kawaoka Y., Corti D., Fremont D.H., Diamond M.S. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 2022;28:490&#x2013;495. doi: 10.1038/s41591-021-01678-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01678-y</ArticleId><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Nair M.S., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130&#x2013;135. doi: 10.1038/s41586-021-03398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora P., Kempf A., Nehlmeier I., Schulz S.R., Jack H.M., Pohlmann S., Hoffmann M. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect. Dis. 2023;23:22&#x2013;23. doi: 10.1016/S1473-3099(22)00733-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00733-2</ArticleId><ArticleId IdType="pmc">PMC9707647</ArticleId><ArticleId IdType="pubmed">36410372</ArticleId></ArticleIdList></Reference><Reference><Citation>Drysdale M., Berktas M., Gibbons D.C., Rolland C., Lavoie L., Lloyd E.J. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: A systematic literature review. Infection. 2024:1&#x2013;23. doi: 10.1007/s15010-023-02098-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02098-5</ArticleId><ArticleId IdType="pubmed">38602623</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014&#x2013;1018. doi: 10.1126/science.abd0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Nirula A., Chen P., Boscia J., Heller B., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:632&#x2013;644. doi: 10.1001/jama.2021.0202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0202</ArticleId><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Xie X., Lin J., Gao P., Wu B., El Sahili A., Su H., Liu Y., Ye X., Tan E.Y., et al. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth. Nat. Commun. 2022;13:5552. doi: 10.1038/s41467-022-33284-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33284-y</ArticleId><ArticleId IdType="pmc">PMC9499943</ArticleId><ArticleId IdType="pubmed">36138032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Zhang X., Zheng P., Dube P.H., Zeng W., Chen S., Cheng Q., Yang Y., Wu Y., Zhou J., et al. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. Cell Res. 2022;32:831&#x2013;842. doi: 10.1038/s41422-022-00700-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00700-3</ArticleId><ArticleId IdType="pmc">PMC9334538</ArticleId><ArticleId IdType="pubmed">35906408</ArticleId></ArticleIdList></Reference><Reference><Citation>Misasi J., Wei R.R., Wang L., Pegu A., Wei C.J., Oloniniyi O.K., Zhou T., Moliva J.I., Zhao B., Choe M., et al. A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization. bioRxiv. :2022. doi: 10.1101/2022.07.29.502029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.29.502029</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckland M.S., Galloway J.B., Fhogartaigh C.N., Meredith L., Provine N.M., Bloor S., Ogbe A., Zelek W.M., Smielewska A., Yakovleva A., et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: A case report. Nat. Commun. 2020;11:6385. doi: 10.1038/s41467-020-19761-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19761-2</ArticleId><ArticleId IdType="pmc">PMC7736571</ArticleId><ArticleId IdType="pubmed">33318491</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirzada R.H., Haseeb M., Batool M., Kim M., Choi S. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells. 2021;10:1052. doi: 10.3390/cells10051052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10051052</ArticleId><ArticleId IdType="pmc">PMC8146643</ArticleId><ArticleId IdType="pubmed">33946869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W.A., II, Eron J.J., Jr., Holman W., Cohen M.S., Fang L., Szewczyk L.J., Sheahan T.P., Baric R., Mollan K.R., Wolfe C.R., et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 2022;14:eabl7430. doi: 10.1126/scitranslmed.abl7430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl7430</ArticleId><ArticleId IdType="pmc">PMC10763622</ArticleId><ArticleId IdType="pubmed">34941423</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J., Andre E., Leyssen P., Neyts J., Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antivir. Res. 2022;198:105252. doi: 10.1016/j.antiviral.2022.105252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105252</ArticleId><ArticleId IdType="pmc">PMC8785409</ArticleId><ArticleId IdType="pubmed">35085683</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussi S.S., Hammond J.L., Gerstenberger B.S., Anderson A.S. Therapeutics for COVID-19. Nat. Microbiol. 2023;8:771&#x2013;786. doi: 10.1038/s41564-023-01356-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-023-01356-4</ArticleId><ArticleId IdType="pubmed">37142688</ArticleId></ArticleIdList></Reference><Reference><Citation>Papini C., Ullah I., Ranjan A.P., Zhang S., Wu Q., Spasov K.A., Zhang C., Mothes W., Crawford J.M., Lindenbach B.D., et al. Proof-of-concept studies with a computationally designed Mpro inhibitor as a synergistic combination regimen alternative to Paxlovid. Proc. Natl. Acad. Sci. USA. 2024;121:e2320713121. doi: 10.1073/pnas.2320713121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2320713121</ArticleId><ArticleId IdType="pmc">PMC11046628</ArticleId><ArticleId IdType="pubmed">38621119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska M., Sepulcri C., Dentone C., Magne F., Balletto E., Baldi F., Labate L., Russo C., Mirabella M., Magnasco L., et al. Triple Combination Therapy with 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clin. Infect. Dis. 2023;77:280&#x2013;286. doi: 10.1093/cid/ciad181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad181</ArticleId><ArticleId IdType="pubmed">36976301</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Casadevall A., Franchini M., Maggi F. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses. 2024;16:217. doi: 10.3390/v16020217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020217</ArticleId><ArticleId IdType="pmc">PMC10891757</ArticleId><ArticleId IdType="pubmed">38399991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei M., Bose D., Nouri-Vaskeh M., Tajiknia V., Zand R., Ghasemi M. Long-term side effects and lingering symptoms post COVID-19 recovery. Rev. Med. Virol. 2022;32:e2289. doi: 10.1002/rmv.2289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2289</ArticleId><ArticleId IdType="pmc">PMC8646420</ArticleId><ArticleId IdType="pubmed">34499784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J., Zhang H., Zhang Y., Lin K., Zhang Y., Wu J., Wan Y., Huang Y., Song J., Fu Z., et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microbes Infect. 2022;11:337&#x2013;343. doi: 10.1080/22221751.2021.2022440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2022440</ArticleId><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandor A.M., Sturdivant M.S., Ting J.P.Y. Influenza Virus and SARS-CoV-2 Vaccines. J. Immunol. 2021;206:2509&#x2013;2520. doi: 10.4049/jimmunol.2001287.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2001287</ArticleId><ArticleId IdType="pmc">PMC8722349</ArticleId><ArticleId IdType="pubmed">34021048</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheul M.K., Nijhof K.H., de Zeeuw-Brouwer M.L., Duijm G., Ten Hulscher H., de Rond L., Beckers L., Eggink D., van Tol S., Reimerink J., et al. Booster Immunization Improves Memory B Cell Responses in Older Adults Unresponsive to Primary SARS-CoV-2 Immunization. Vaccines. 2023;11:1196. doi: 10.3390/vaccines11071196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071196</ArticleId><ArticleId IdType="pmc">PMC10384172</ArticleId><ArticleId IdType="pubmed">37515012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilapitiya D., Wheatley A.K., Tan H.X. Mucosal vaccines for SARS-CoV-2: Triumph of hope over experience. EBioMedicine. 2023;92:104585. doi: 10.1016/j.ebiom.2023.104585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104585</ArticleId><ArticleId IdType="pmc">PMC10154910</ArticleId><ArticleId IdType="pubmed">37146404</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen C.K., Wong W.M., Mak L.F., Lam J.Y., Cheung L.Y., Cheung D.T., Ng Y.Y., Lee A.C., Zhong N., Yuen K.Y., et al. An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models. Nat. Commun. 2023;14:6762. doi: 10.1038/s41467-023-42349-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42349-5</ArticleId><ArticleId IdType="pmc">PMC10598001</ArticleId><ArticleId IdType="pubmed">37875475</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Wei Y., Yang H., Yan J., Li X., Li Z., Zhao Y., Liang H., Wang H. Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines. 2022;10:2035. doi: 10.3390/vaccines10122035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122035</ArticleId><ArticleId IdType="pmc">PMC9785936</ArticleId><ArticleId IdType="pubmed">36560445</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonam S.R., Hu H. Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. Zoonoses. 2023:3. doi: 10.15212/ZOONOSES-2023-0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.15212/ZOONOSES-2023-0003</ArticleId><ArticleId IdType="pmc">PMC10686570</ArticleId><ArticleId IdType="pubmed">38031548</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo-Romero J.A., Chingate-Lopez S.M., Camacho B.A., Almeciga-Diaz C.J., Ramirez-Segura C.A. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19. Heliyon. 2024;10:e26423. doi: 10.1016/j.heliyon.2024.e26423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e26423</ArticleId><ArticleId IdType="pmc">PMC10907543</ArticleId><ArticleId IdType="pubmed">38434363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>